ArticleJournal of virology2025
Ceramide synthase 4 interferes with replication of influenza virus but is downregulated by infection.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Measles virus reprograms CD4Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Influenza continues to pose a serious threat to humans. Influenza-host interaction is incompletely understood, requiring identification of host factors that regulate viral pathogenicity. Ceramide synthases (CerSs) are responsible for producing and controlling ceramide levels within cells. Ceramides are structural and signaling sphingolipid components that mediate various biological functions and affect the infectivity of multiple viruses. However, the role of CerSs during virus infections remains unclear. In this study, we investigated the possible function of CerSs in host defense against influenza virus infection. Cells stably expressing CerS4 poorly supported influenza virus replication, whereas CerS1 did not affect replication. Transient overexpression of CerS4 also impaired the efficient production of viral proteins as well as infectious progeny viruses. In support of these results, knockdown of endogenous CerS4 in cells enhanced virus replication. Intriguingly, CerS4 impeded virus-induced activation of cellular c-Jun N-terminal kinase (JNK), which interfered with influenza viral replication. On the other hand, influenza virus infection was shown to induce CerS4 ubiquitination and downregulation, which could limit the antiviral activity of CerS4. Collectively, these findings reveal a new function of CerS4 that restricts influenza virus infection and provides valuable insights into influenza-host defense interactions.IMPORTANCESeasonal influenza causes serious public health problems in the world with substantial annual morbidity and mortality. Further, there have been persistent concerns about potential development of an influenza pandemic. Current antiviral drugs are limited in their efficacy, especially due to the rapid emergence of drug-resistant variants. Host protein-directed therapy is an alternative or complementary approach to broadly controlling influenza virus infections but requires a deeper understanding of influenza-host interplay. Host ceramide synthase 4 regulates the level of ceramides that possess both structural and signaling mediator functions. Our study reveals that ceramide synthase 4 displays an antiviral activity against influenza virus infection by regulating JNK activation. However, influenza virus triggers degradation of ceramide synthase 4, which could favor virus replication. The findings advance our knowledge about the ceramide network interaction with influenza and provide a framework for developing a host-targeted therapy to cure influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.